Abstract: A therapeutic composition which contains a potentiating or safening amount of an aqueous surfactant in combination with a bactericidal agent and/or a biological response modifier is described herein. The disclosure further describes an improved method for treating mastitis by administering the composition to an afflicted mammal. Additionally, the disclosure describes a method for screening suitable formulations for treating infectious diseases.
Type:
Grant
Filed:
December 20, 1991
Date of Patent:
August 30, 1994
Assignee:
American Cyanamid Company
Inventors:
Michael J. Daley, William D. Steber, Gary J. Furda, Paul A. Johnston, Elizabeth R. Oldham
Abstract: A stabilized composition comprising an effective amount of non-glycosylated recombinant human IL2 in reduced form, citric acid, mannitol and a preservative effective amount of a mixture of dextran and mono-calcium and disodium ethylenediamine tetraacetate, particularly in lyophilized form.
Abstract: A process for the preparation of acyl phosphate esters of the formula I or salts thereof: ##STR1## wherein R and R.sup.1 are the same or different and represent a linear or branched alkyl group having up to 4 carbon atoms, phenyl or benzyl;n is an integer;when n is 1, R.sup.2 represents the group ##STR2## wherein R.sup.4 is a linear or branched alkyl, alkenyl or alkynyl, a cyclic alkyl, a cyclic alkenyl, or aryl which may be substituted by alkyl, alkenyl, alkynyl, aryl, arylalkyl, or arylalkenyl, orwhen n is at least 2, R.sup.2 represents the group ##STR3## wherein R.sup.4 is as defined above. Novel compounds of the formula I wherein n is at least 2, and modified hemoglobin obtained using the novel compounds are also provided.
Abstract: There is disclosed a composition for measurement of potassium ion concentration, which contains a) pyruvate kinase, b) glycerol kinase, c) glycerol-3-phosphate oxidase, d) peroxidase, e) a chromogen of reduced type, f) adenosine diphosphate or a salt thereof, and g) phosphoenolpyruvic acid or a salt thereof. Also disclosed is a composition for elimination of ammonium ions, which contains a) glutamate dehydrogenase, b) glucose dehydrogenase, and c) nicotinamide adenine dinucleotide of reduced type (NADH) or nicotinamide adenine dinucleotide phosphate of reduced type (NADPH).
Abstract: Sialic acid binding proteins, sialic acid-binding peptides and sialic acid containing oligo-saccharides are active ingredients of a novel bacterial enterotoxin neutralizer and interfere with the binding of enterotoxins, including cholera toxin, to receptors so as to exert an effect of neutralizing the toxicity, thus being utilized as an effective neutralizer and are safe and available cheaply and abundantly from by-products produced during the processing of cow's milk which renders the enterotoxin neutralizer economically advantageous for commercial use.
Abstract: The invention relates to a method of purifying basic fibroblast growth factor. The method involves the use of strong cation exchange chromatography followed by hydrophobic interaction chromatography and then by weak cation exchange chromatography.
Type:
Grant
Filed:
April 12, 1993
Date of Patent:
July 19, 1994
Assignee:
Scios Nova Inc.
Inventors:
Paula J. Shadle, Kate B. Silverness, Robert S. King
Abstract: Method of preparing a lipoprotein modified by incorporation of at least one lipophilic active substance other than a triglyceride, characterized by incorporation of said active substance into an emulsion of a lipid phase in a continuous aqueous phase, by adding to the emulsion, with stirring, an original lipoprotein and at least one lipid transfer protein, allowing the mixture to incubate, and, using known methods, isolating the lipoprotein into which the active substance is incorporated; a lipoprotein thus obtained, and pharmaceutical or cosmetic composition containing such a modified lipoprotein.
Type:
Grant
Filed:
May 6, 1992
Date of Patent:
June 28, 1994
Assignees:
Universite Droit et Sante Lille II, Universite Paul Sabatier Toulouse III
Inventors:
Gilles Favre, Patrick Duriez, Francoise Monard, Samadi-Baboli Medhi, Georges Soula, Jean-Charles Fruchart
Abstract: The protein fraction from Leguminosae seeds, which is characterized by at least one band in polyacrylamide gel electrophoresis with sodium dodecyl sulfate, by relative molecular masses from 3,000 to 30,000 g/mole, by a content of total nitrogen of 14 to 20% and amino nitrogen of 1 to 2% related to the protein content and by further parameters defined in claim 1, is appropriate for the care of skin and for the treatment of inflammatory skin diseases, whereby the protein fraction is generally used as a concentrate of active substances or e.g. as a cream, lotion, emulsion, gel, face mask, powder or plaster.
Type:
Grant
Filed:
September 11, 1992
Date of Patent:
June 21, 1994
Assignee:
Pentapharm AG
Inventors:
Rainer Voegeli, Kurt Stocker, Christian Mueller
Abstract: The present invention relates to the use of INHIB in the detection and inhibition of inflammation. INHIB is structurally identical to the C3 .beta.-chain.
Abstract: The invention comprises proteinaceous substances isolated from crude Ornithodoros moubata extract which inhibit adhesion of platelets to collagen. These substances do not inhibit platelet adhesion to fibrinogen, and are therefore particularly useful for inhibiting adhesion of platelets to collagen when simultaneous inhibition of platelet adhesion to fibrinogen is undesired. They are particularly useful in the prevention, prophylaxis, therapy and treatment of thrombotic diseases.
Type:
Grant
Filed:
December 10, 1991
Date of Patent:
June 14, 1994
Assignee:
Merck & Co., Inc.
Inventors:
Thomas M. Connolly, Michael Neeper, Lloyd Waxman
Abstract: A method of preparing fibrinogen concentrate from blood plasma by cooling said plasma from a temperature above 0.degree. C. to a first temperature between -10.degree. C. and -40.degree. C., thawing the solid material thus obtained to a temperature near the freezing point of water and subsequently physically separating the solid matter and the liquid main fraction of the plasma, viz. water, whereby the thawing is effected in steps from the first temperature to a conditioning temperature between -5.degree. C. and -1.degree. C., after which the size of the solid material is reduced and the reduced material is brought to a temperature at which the main fraction of the plasma, viz. water, becomes liquid and the solubility of fibrinogen in said fluid is as low as possible, after which fluid is separated from the fibrinogen concentrate. The invention also relates to a device for carrying out this method.
Type:
Grant
Filed:
July 17, 1992
Date of Patent:
June 14, 1994
Assignee:
Harimex-Ligos B.V.
Inventors:
Frederik S. van Dommelen, Gerrit Wijngaards
Abstract: A method of stimulating angiogenesis in a mammal by administering to a mammal a haptoglobin in an amount effective to stimulate angiogenesis, and a pharmaceutical composition containing a haptoglobin and a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
September 2, 1992
Date of Patent:
June 7, 1994
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Maria C. Cid, Derrick S. Grant, Hynda K. Kleinman, Gary S. Hoffman
Abstract: In a method of recovering proteins, an antibody raised against a peptide comprising at least a fragment of the protein is immobilized on a solid support, a crude preparation of the protein is contacted with the antibody under conditions resulting in a partial, reversible unfolding of the protein to obtain binding of the protein to the antibody, and the protein is eluted from the solid support under non-denaturing conditions to recover the protein in a form in which it is refolded into its native conformation.
Abstract: A method for attaching technetium-99m to proteins using reducing metal reagents to achieve binding to high affinity binding sites and high specific activity. The reagents play a dual role under the given experimental conditions by reducing disulfide bonds in the proteins to sulfhydral groups suitable for binding to technetium, and reducing pertechnetate from Tc(VII) to Tc(III) or Tc(V). Reduction of disulfide on the protein is conducted initially with an excess of reducing metal reagent, a pertechnetate reagent is added at the end of the protein reduction reaction and allowed to continue to reduce the technetium. Thereafter a chelator scavenger is added to remove poorly bound or unbound technetium.
Abstract: The present invention relates to novel peptides of formulaeXaa Glu Asp Cys Lys (SEQ I.D. No: 1),andGlu Asp Cys Lys (SEQ I.D. No: 2)wherein the Cys sulfur is bonded to an acetamidomethyl group, and Xaa is pyro-Glu, the acid addition salts thereof, the pharmaceutical compositions comprising the same and a process for the preparation of the novel peptides and compositions.The novel peptides selectively inhibit the proliferation of hemopoietic cells.The invention also covers the treatment of mammals (including human beings) with the said peptides and compositions for selectively inhibiting the proliferation of hemopoietic cells.The advantage of the novel compounds is that they are almost completely harmless, they do not have any side-effect in therapeutic dose-range, in addition they significantly inhibit the damaging effects of drugs and radiation used for the therapy of tumorous diseases or the dose of drug or radiation can be increased when they are administered.
Type:
Grant
Filed:
May 17, 1994
Date of Patent:
May 17, 1994
Assignee:
Richter Gedeon Vegyeszeti Gyar Rt.
Inventors:
Andras Balazs, Istvan Schon, Tamas Szirtes, Lajos Kisfaludy, deceased
Abstract: The LTD.sub.4 receptor has been defined by radioligand binding studies as a member of the family of G-protein coupled receptors. A photoactivable azido derivative of LTD.sub.4 ([.sup.125 I]Azido-LTD.sub.4) has been synthesized for use as a photoaffinity probe. Photoactivation of ([.sup.125 I]Azido-LTD.sub.4 under equilibrium binding conditions revealed the selective radiolabeling of a 45 kDa protein in guinea-pig lung membranes, as visualized by SDS-PAGE and autoradiography.
Abstract: A glycosaminoglycan-modified protein wherein an amino group of a protein is bound to an aldehyde group, which has been formed by reducing and partially oxidizing the reducing terminal sugar moiety of a glycosaminoglycan, which has a high stability in vivo and can retain physiological activity of the protein for a prolonged period of time.
Abstract: A method for separating phytate and manganese from protein and dietary fiber involves treatment of an aqueous slurry of phytatecontaining material at a low pH with insoluble alumina. In a batch treatment process the pH of the solution is increased, leaving phytate units attached to the alumina while freeing the protein and dietary fiber. In a column treatment process, the column containing alumina is rinsed, after the low pH treatment, with dilute acid and water to recover the protein and/or dietary fiber. This method may be employed either during the manufacture of protein and fiber isolates from flour or flakes, or for removing phytate from commercially available protein and fiber commodities. The spent alumina may be readily regenerated and reused. A method of separating manganese from rice protein using this same technology is also disclosed.
Type:
Grant
Filed:
June 7, 1993
Date of Patent:
April 26, 1994
Assignee:
Abbott Laboratories
Inventors:
Terrence B. Mazer, Christy A. Nardelli, Arthur J. C. L. Hogarth, Andre Daab-Krzykowski
Abstract: This invention relates to the field of immune therapy of cancer, more specifically to immunoconjugates of a cytotoxic moiety with a targeting moiety, more specifically to immunoconjugates of antibodies or fragments or functional derivatives of antibodies coupled to a cytotoxic substance such as drugs, toxins or radioisotopes. It especially relates to the release of substances bound to a targeting moiety through the use of acid-cleavable linker molecules.
Type:
Grant
Filed:
December 31, 1991
Date of Patent:
April 26, 1994
Assignee:
Akzo N.V.
Inventors:
Petrus J. Boon, Franciscus M. Kaspersen, Ebo S. Bos
Abstract: The invention features a method for inhibiting proliferation of osteoblasts in a mammal in need of such inhibition. The method entails administering PF4. PF4 can be used to treat both diseases characterized by primary changes in osteoblastic cell function/activity (e.g., ossifying fibroma and fibrous dysplasia, osteoblastoma and osteoid osteoma, and osteosarcoma) and diseases or systemic conditions affecting bone in which abnormal osteoblastic cell function/activity is a secondary effect (e.g., acromegaly, hypercalcemia, primary or secondary hyperparathyroidism, hyperthyroidism, osteoporosis, or Paget's disease of bone). In addition, PF4 may be used to treat diseases associated with localized changes in bone metabolism in which abnormal osteoblastic cell function/activity contributes to pathogenic bone changes.
Type:
Grant
Filed:
August 28, 1992
Date of Patent:
April 19, 1994
Assignee:
University of Louisville Research Foundation, Inc.